Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hebei Grandios Pharma Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to AULAKH, CHARANJIT, who is the 1 examiner and the busiest examiner for the company with 1 pending file. The prosecution is localized in 1 distinct art unit, reflecting a focused technical review. For a patent practitioner, the concentration of 1 pending office action under 1 examiner means that the immediate prosecution strategy is singular.
There is no need to coordinate across different art units or examiner styles at this time. The workload is minimal, with AULAKH, CHARANJIT handling the entirety of the company's pending USPTO matters. Practitioners should prioritize direct communication with AULAKH, CHARANJIT to resolve the 1 pending office action efficiently. This streamlined profile suggests a very specific interaction with the patent office in the Biotechnology & Pharmaceuticals sector. The lack of diversity in examiners and art units simplifies the administrative process but places high importance on the outcome of this 1 matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18813075 | DIBENZODIAZEPINE COMPOUNDS AND USE IN INTERFERON ACTIVATOR PROTEIN AGONISTS THEREOF | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18813075 | DIBENZODIAZEPINE COMPOUNDS AND USE IN INTERFERON ACTIVATOR PROTEIN AGONISTS THEREOF | AULAKH, CHARANJIT | 1621 | §102§112 | Non-Final OA | — | Pending | Aug 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHebei Grandios Pharma Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of Hebei Grandios Pharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.